Newman Ferrara LLP Announces Corporate Governance Investigation of OvaScience, Inc.
February 14 2017 - 12:57PM
Business Wire
Newman Ferrara LLP announced today that the firm is conducting
an investigation on behalf of shareholders of OvaScience, Inc.
(“OvaScience” or the “Company”) (NASDAQ:OVAS) into potential
breaches of fiduciary duty by the Company’s Board of Directors (the
“Board”).
OvaScience, headquartered in Waltham, MA, is a company focused
on the development and marketing of fertility treatment for women.
Newman Ferrara’s investigation focuses on decisions made by the
Board, without shareholder approval, the result of which
significantly diminish shareholder value and do not benefit the
Company. Considering the Company’s lackluster performance since its
2013 initial public offering, it is clear that the Board lacks the
ability to fairly assess and oversee the Company’s direction and
leadership.
Current OvaScience stockholders seeking more information on this
matter are invited to contact Newman Ferrara attorneys Jeffrey
Norton (jnorton@nfllp.com) or Roger Sachar, Jr. (rsachar@nfllp.com)
to discuss this investigation and their rights.
Newman Ferrara maintains a multifaceted practice based in New
York City with attorneys specializing in complex commercial and
multi-party litigation, securities fraud and shareholder
litigation, consumer protection, civil rights, and real estate. For
more information, please visit the firm website at
www.nfllp.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170214006156/en/
Newman Ferrara LLPJeffrey M. Norton,
212-619-5400jnorton@nfllp.com
Ovascience Inc. (delisted) (NASDAQ:OVAS)
Historical Stock Chart
From Apr 2024 to May 2024
Ovascience Inc. (delisted) (NASDAQ:OVAS)
Historical Stock Chart
From May 2023 to May 2024